Nasdaq

Allergan, an AbbVie Company, Announces Positive Topline Phase 3 Results Evaluating Investigational Twice-Daily Administration of VUITY™ (pilocarpine HCI ophthalmic solution ...

VUITY is the first and only eye drop to treat presbyopia, or age-related blurry near vision, in adults and is FDA-approved for once-daily administration In the VIRGO trial evaluating twice-daily ...
Nasdaq

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

A total of 29 abstracts, including three late-breaking presentations, demonstrate AbbVie and Allergan Aesthetics' shared commitment to advancing science across a spectrum of immune-mediated ...
Morningstar

Allergan Aesthetics Announces Expansion of SKINVIVE by JUVÉDERM® into 35 New Markets, Reinforcing its Commitment to Advancing Global Skin Quality

IRVINE, Calif., Sept. 23, 2025 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the roll-out of SKINVIVE by JUVÉDERM® in 35 additional markets this year bringing ...
Business Insider

Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar Lines

–All primary and secondary endpoints were met for both Phase 3 studies (M21-500 and M21-508). –Results support BoNT/E as a novel botulinum neurotoxin serotype E characterized by a rapid onset of ...
Morningstar

Natrelle® Awarded Supplier Agreement from Vizient

This agreement grants Vizient clients enhanced access to Natrelle®, the broadest selection of breast implant options on the market. IRVINE, Calif., Oct. 1, 2025 /PRNewswire/ -- Allergan Aesthetics, an ...